NCT06580444View on ClinicalTrials.gov

Brexanolone to Target Concurrent PTSD and Stress Induced Alcohol Use in Veterans: A Dose Finding Study

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 28, 2025

Primary Completion Date

February 26, 2027

Study Completion Date

March 19, 2027

Conditions
Alcohol Use Disorder (AUD)Post Traumatic Stress Disorder (PTSD)
Interventions
DRUG

Brexanolone

The participant will receive either a placebo, or 90, 60, or 30 mcg/kg/hr of Brexanolone over a 20-hour period intravenous infusion.

Sponsors

Collaborators (1)

Sage Therapeutics
All Listed Sponsors
collaborator

United States Department of Defense

FED

collaborator

Congressionally Directed Medical Research Programs

FED

collaborator

VA Connecticut Healthcare System

FED

collaborator

Sage Therapeutics

INDUSTRY

collaborator

RTI International

OTHER

collaborator

Yale University

OTHER

lead

Pharmacotherapies for Alcohol and Substance Use Disorders Alliance

OTHER

NCT06580444 - Brexanolone to Target Concurrent PTSD and Stress Induced Alcohol Use in Veterans: A Dose Finding Study | Biotech Hunter | Biotech Hunter